Zamani E. D. Cele

Zamani E. D. Cele

Auto-generated profile, based on publicly available information

Zamani E. D. Cele

Bio‐polymer Modification and Advanced Therapeutics Laboratory, Centre For Nanostructures and Advanced Materials CSIR Pretoria Gauteng South Africa

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in ACS Omega
Verified
Journal Article
Closed access
ZCZamani E.D. Cele
Zamani E.D. Cele
ASAnou M Somboro
Anou M Somboro
DADaniel G. Amoako
Daniel G. Amoako
LNLindokuhle F. Ndlandla
Lindokuhle F. Ndlandla
MBMohammed O. Balogun
Mohammed O. Balogun

24 August 2023 in ACS Omega
Verified
Journal Article
Open access
ZCZamani E. D. Cele
Zamani E. D. Cele
WMWilliam Matshe
William Matshe
LMLindani Mdlalose
Lindani Mdlalose
KSKatlego Setshedi
Katlego Setshedi
KMKanyane Malatji
Kanyane Malatji
MBMohammed Balogun
Mohammed Balogun
Cationic chitosan derivatives have been widely studied as potential antimicrobial agents. However, very little is known about their antiviral activity and mode of action against enveloped viruses. We investigated the ability of hydroxypropanoic acid-grafted chitosan (HPA-CS) and N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC) to inactivate enveloped viruses like the human immunodeficiency virus (HIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The membrane-disrupting potential of the chitosan derivatives was initially investigated in a hemolysis assay. At 1.0 mg/mL, about 80% hemolysis was observed for the cationic chitosan derivatives, which was significant when compared to almost no membrane-disrupting activity by the unmodified chitosan. Virus inhibition was evaluated using the luciferase-based antiviral assay against the HIV-1 NL4.3 virus (400 TCID). The IC50 of HPA-CS was 4.109 mg/mL, while the HTCC showed a higher antiviral activity at an IC50 = 0.225 mg/mL. For practical application, the antiviral efficacies of the HTCC-coated and uncoated nonmedical masks were evaluated for SARS- CoV-2 virus capture. The coated masks demonstrated an almost excellent performance with nearly 100% viral inhibition compared to less than 60% inhibition by the uncoated masks. Molecular docking predictions suggest that the HTCC polymers interact with the viral spike protein, blocking the coronavirus interaction with the target host cell's angiotensin-converting enzyme 2 cellular receptors.

14 April 2023 in Macromolecular Bioscience
Verified
Journal Article
Open access
WMWilliam M.R. Matshe
William M.R. Matshe
LTLesego L. Tshweu
Lesego L. Tshweu
SMSindisiwe Mvango
Sindisiwe Mvango
ZCZamani E.D. Cele
Zamani E.D. Cele
ACAvashnee S. Chetty
Avashnee S. Chetty
MBMohammed Balogun
Mohammed Balogun
Uncomplicated malaria is effectively treated with oral artemisinin‐based combination therapy (ACT). Yet, there is an unmet clinical need for the intravenous treatment of the more fatal severe malaria. There is no combination intravenous therapy for uncomplicated due to the nonavailability of a water‐soluble partner drug for the artemisinin, artesunate. The currently available treatment is a two‐part regimen split into an intravenous artesunate followed by the conventional oral ACT . In a novel application of polymer therapeutics, the aqueous insoluble antimalarial lumefantrine is conjugated to a carrier polymer to create a new water‐soluble chemical entity suitable for intravenous administration in a clinically relevant formulation . The conjugate is characterized by spectroscopic and analytical techniques, and the aqueous solubility of lumefantrine is determined to have increased by three orders of magnitude. Pharmacokinetic studies in mice indicate that there is a significant plasma release of lumefantrine and production its metabolite desbutyl‐lumefantrine (area under the curve of metabolite is ≈10% that of the parent). In a Plasmodium falciparum malaria mouse model, parasitemia clearance is 50% higher than that of reference unconjugated lumefantrine. The polymer‐lumefantrine shows potential for entering the clinic to meet the need for a one‐course combination treatment for severe malaria.

12 February 2026 in Advanced Therapeutics
Verified
Journal Article
Open access
TGThenesia R. Govender
Thenesia R. Govender
WMWilliam M. R. Matshe
William M. R. Matshe
NDNokuthula Dube
Nokuthula Dube
ZCZamani E. D. Cele
Zamani E. D. Cele
AWAurelia Alvina Williams
Aurelia Alvina Williams
MBMohammed Balogun
Mohammed Balogun
Polymer–drug conjugates have seen limited exploration in antimalarial therapy, despite their successful development for cancer and other diseases. With rising resistance and a critical shortage of first‐line treatments for severe malaria, innovative drug delivery strategies are urgently needed to maximize the currently available drugs. Building on our previous work that demonstrated a water‐soluble polymer–lumefantrine conjugate for the intravenous treatment of severe malaria, we investigated the influence of linker chemistry on drug release rate and kinetics of a new polyethylene glycol‐lumefantrine conjugate under conditions relevant to malaria pathophysiology. Four homologous aliphatic diacid linkers (succinic, glutaric, adipic, and dodecanedioic acids) containing 4, 5, 6, and 12 carbon atoms, respectively, were introduced between the polymer and the drug. The conjugates were structurally well‐defined and selectively cleaved at the ester bond under acidic conditions (pH 5.5), releasing only free lumefantrine, while remaining stable in human plasma (pH 7.4). Drug release rates were inversely proportional to linker length, with only the succinic acid‐linked conjugate, which exhibited an initial burst release, deviating from first‐order kinetic models. Complete inhibition of the Plasmodium falciparum NF54 strain was observed in vitro with a divalent variant of the succinic acid‐linked conjugate, underscoring its potential for effective therapeutic action.